- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Traws Pharma Inc (TRAW)
Traws Pharma Inc stock price live, this page displays NASDAQ TRAW stock exchange data. View the TRAW premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Traws Pharma Inc real time stock price chart below.
What Is the Traws Pharma Inc Stock Price Today?
The Traws Pharma Inc stock price today is 2.580.
What Is the Stock Symbol for Traws Pharma Inc?
The stock symbol for Traws Pharma Inc is "TRAW."
What Stock Exchange Does Traws Pharma Inc Trade On?
Traws Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is Traws Pharma Inc a Good Stock to Buy?
Determining whether Traws Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TRAW quote. (ISIN: US68232V8845)
What Is the Traws Pharma Inc Stock Price Today?
The Traws Pharma Inc stock price today is 2.580.
What Is the Stock Symbol for Traws Pharma Inc?
The stock symbol for Traws Pharma Inc is "TRAW."
What Stock Exchange Does Traws Pharma Inc Trade On?
Traws Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is Traws Pharma Inc a Good Stock to Buy?
Determining whether Traws Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TRAW quote. (ISIN: US68232V8845)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.990
2.620
52 wk Range
0.970
8.610
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9902.620
52 wk Range
0.9708.610
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TRAW Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.000
Upside
+210.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Onconova Th receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Traws Pharma Inc For: 17 December
- Investing.com
- Form 8K Traws Pharma Inc For: 17 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Traws Pharma Inc Company Profile
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Traws Pharma Inc Earnings Call Summary for Q2/2025
- Revenue surged to $2.7M in Q2 2025, up from $57K in Q2 2024; stock rose 17% premarket
- Net loss narrowed to $900K from $123.1M year-over-year; R&D expenses decreased to $2.3M
- Cash position at $13.1M, down from $21.3M at end of 2024; company maintains healthy current ratio of 1.81
- EPS forecasts for FY2025 and FY2026 set at $30.31 and $62.39 respectively; profitability expected this year
- COVID-19 phase two study results expected by end of 2025; ongoing discussions with FDA and BARDA
Last Updated: 2025-08-14, 09:32 a/m
Read Full TranscriptCompare TRAW to Peers and Sector
Metrics to compare | TRAW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRAWPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −2.5x | −0.6x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | 4.5x | 0.2x | 2.6x | |
Price / LTM Sales | 7.2x | 7.6x | 3.4x | |
Upside (Analyst Target) | 210.1% | 165.9% | 42.0% | |
Fair Value Upside | Unlock | 13.4% | 5.8% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.000
(+210.08% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.34 / -9.16
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Traws Pharma (TRAW) Stock Price Today?
The Traws Pharma stock price today is 2.580
What Stock Exchange Does Traws Pharma Trade On?
Traws Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Traws Pharma?
The stock symbol for Traws Pharma is "TRAW."
What Is the Traws Pharma Market Cap?
As of today, Traws Pharma market cap is 20.62M.
What Is Traws Pharma's Earnings Per Share (TTM)?
The Traws Pharma EPS (TTM) is -1.38.
From a Technical Analysis Perspective, Is TRAW a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Traws Pharma Stock Split?
Traws Pharma has split 4 times.
How Many Employees Does Traws Pharma Have?
Traws Pharma has 7 employees.
What is the current trading status of Traws Pharma (TRAW)?
As of Jan 21, 2026, Traws Pharma (TRAW) is trading at a price of 2.580, with a previous close of 2.580. The stock has fluctuated within a day range of 1.990 to 2.620, while its 52-week range spans from 0.970 to 8.610.
What Is Traws Pharma (TRAW) Price Target According to Analysts?
The average 12-month price target for Traws Pharma is USD8.000, with a high estimate of USD8 and a low estimate of USD8. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +210.08% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.